Legend Biotech (LEGN) Tops Q4 EPS by 9c

Legend Biotech (NASDAQ: LEGN) reported Q4 EPS of ($0.16), $0.09 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $186.52 million versus the consensus estimate of $173.99 million.

For earnings history and earnings-related data on Legend Biotech (LEGN) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Oppenheimer Downgrades Legend Biotech Corp. (LEGN) to Perform, 'CEO/Partnership/Competition Overhangs to Cap Upside'
• Phillips 66, Marathon Merger Talks Collapsed - Semafor